Aldeyra Therapeutics (ALDX) Tops Q2 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Aldeyra Therapeutics (ALDX) Tops Q2 EPS by 9c

Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update

August 6, 2020 7:00 AM EDT

Based on FDA Agreement that RASP is an Objective Sign of Dry Eye Disease, Assessment of Tear RASP Levels in Dry Eye Disease Patients Expected to Begin in the Fourth Quarter of 2020

New Drug Application (NDA) Submission for Reproxalap in Dry Eye Disease Expected by the End of 2021

Current Cash Expected to Support Operations Through 2022, Including Potential Approvals for Dry Eye Disease and Allergic Conjunctivitis

Management to Host Conference Call at 8:00 a.m. ET Today

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a... More